메뉴 건너뛰기




Volumn 23, Issue 2, 2014, Pages 255-263

Clofarabine in the treatment of myelodysplastic syndromes

Author keywords

Clofarabine; Myelodysplastic syndrome; Pharmacodynamic; Pharmacokinetic; Purine nucleoside analogs

Indexed keywords

CLOFARABINE; CYTARABINE; DNA METHYLTRANSFERASE INHIBITOR;

EID: 84892400905     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.877887     Document Type: Article
Times cited : (6)

References (41)
  • 2
    • 52649154001 scopus 로고    scopus 로고
    • A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome
    • Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008;112:1638-45
    • (2008) Blood , vol.112 , pp. 1638-1645
    • Faderl, S.1    Ravandi, F.2    Huang, X.3
  • 3
    • 84886859143 scopus 로고    scopus 로고
    • Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival
    • Burnett AK, Russell NH, Hunter AE, et al. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood 2013;122:1384-94
    • (2013) Blood , vol.122 , pp. 1384-1394
    • Burnett, A.K.1    Russell, N.H.2    Hunter, A.E.3
  • 4
    • 0037276433 scopus 로고    scopus 로고
    • Antitumor activity of 2-fluoro-2′-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase
    • DOI 10.1038/sj.cgt.7700520
    • Parker WB, Allan PW, Hassan AE, et al. Antitumor activity of 2-fluoro-2-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase. Cancer Gene Ther 2003;10:23-9 (Pubitemid 36222073)
    • (2003) Cancer Gene Therapy , vol.10 , Issue.1 , pp. 23-29
    • Parker, W.B.1    Allan, P.W.2    Hassan, A.E.A.3    Secrist III, J.A.4    Sorscher, E.J.5    Waud, W.R.6
  • 5
    • 0026533461 scopus 로고
    • Oral antilymphocyte activity and induction of apoptosis by 2-chloro 2-arabino-fluoro-2 deoxyadenosine
    • Carson DA, Wasson DB, Esparza LM, et al. Oral antilymphocyte activity and induction of apoptosis by 2-chloro 2-arabino-fluoro-2 deoxyadenosine. Proc Natl Acad Sci USA 1992;89:2970-4
    • (1992) Proc Natl Acad Sci USA , vol.89 , pp. 2970-2974
    • Carson, D.A.1    Wasson, D.B.2    Esparza, L.M.3
  • 7
    • 0029053894 scopus 로고
    • Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-D- arabinofuranosyl) adenine in human lymphoblastoid cells
    • Xie C, Plunkett W. Metabolism and actions of 2-chloro-9-(2-deoxy-2- fluoro-D-arabinofuranosyl) adenine in human lymphoblastoid cells. Cancer Res 1995;55:2847-52
    • (1995) Cancer Res , vol.55 , pp. 2847-2852
    • Xie, C.1    Plunkett, W.2
  • 10
    • 30044450909 scopus 로고    scopus 로고
    • A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems
    • King KM, Damaraju VL, Vickers MF, et al. A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems. Mol Pharmacol 2006;69:34-53
    • (2006) Mol Pharmacol , vol.69 , pp. 34-53
    • King, K.M.1    Damaraju, V.L.2    Vickers, M.F.3
  • 11
    • 0029927229 scopus 로고    scopus 로고
    • Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-(2-deoxy-fluoro-beta-D-arabinofuranosyl) adenine
    • Xie KC, Plunkett W. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-(2-deoxy-fluoro-beta-D- arabinofuranosyl) adenine. Cancer Res 1996;56:3030-7
    • (1996) Cancer Res , vol.56 , pp. 3030-3037
    • Xie, K.C.1    Plunkett, W.2
  • 12
    • 0025811415 scopus 로고
    • Effects of 2-chloro-9-(2-deoxy-2-fluorobeta-D-arabinofuranosyl) adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by 5'-triphosphate
    • Parker WB, Shaddix SC, Chang CH, et al. Effects of 2-chloro-9-(2-deoxy-2- fluorobeta-D-arabinofuranosyl) adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by 5'-triphosphate. Cancer Res 1991;51:2386-94
    • (1991) Cancer Res , vol.51 , pp. 2386-2394
    • Parker, W.B.1    Shaddix, S.C.2    Chang, C.H.3
  • 13
    • 0033063791 scopus 로고    scopus 로고
    • Comparison of the mechanism of cytotoxicity of 2-chloro-9,(2-deoxy-2- fluoro-β-D-arabinofuranosyl)adenine, 2-chloro-9-(2-deoxy-2-fluoro-β-D- ribofuranosyl)adenine, and 2-chloro-9-(2-deoxy-2,2-difluoro-β-D- ribofuranosyl)adenine in CEM cells
    • Parker WB, Shaddix SC, Rose L, et al. Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine, 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine, 2-chloro-9-(2-deoxy-2, 2-difluoro-beta-Dribofuranosyl) adenine in CEM cells. Mol Pharmacol 1999;55:515-20 (Pubitemid 29128108)
    • (1999) Molecular Pharmacology , vol.55 , Issue.3 , pp. 515-520
    • Parker, W.B.1    Shaddix, S.C.2    Rose, L.M.3    Shewach, D.S.4    Hertel, L.W.5    Secrist III, J.A.6    Montgomery, J.A.7    Bennett Jr., L.L.8
  • 14
    • 0023733094 scopus 로고
    • Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases DNA primase, and ribonucleotide reductase
    • Parker WB, Bapat AR, Shen JX, et al. Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase. Mol Pharmacol 1988;34:485-91
    • (1988) Mol Pharmacol , vol.34 , pp. 485-491
    • Parker, W.B.1    Bapat, A.R.2    Shen, J.X.3
  • 15
    • 0034669944 scopus 로고    scopus 로고
    • Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria
    • Genini D, Adachi S, Chao Q, et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000;96:3537-43
    • (2000) Blood , vol.96 , pp. 3537-3543
    • Genini, D.1    Adachi, S.2    Chao, Q.3
  • 17
    • 84892376441 scopus 로고    scopus 로고
    • Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer
    • Bonate PL, Cunningham CC, Gaynon P. Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer. Clin Cancer Res 2003;9:6335-42
    • (2003) Clin Cancer Res , vol.9 , pp. 6335-6342
    • Bonate, P.L.1    Cunningham, C.C.2    Gaynon, P.3
  • 18
    • 67650798203 scopus 로고    scopus 로고
    • Effect of clofarabine on lymphocyte populations in patients treated for solid tumors
    • abstract 21134
    • Cunningham C, Nemunaitis J, Senzer N, et al. Effect of clofarabine on lymphocyte populations in patients treated for solid tumors. J Clin Oncol 2007;25:abstract 21134
    • (2007) J Clin Oncol , vol.25
    • Cunningham, C.1    Nemunaitis, J.2    Senzer, N.3
  • 19
    • 70349771790 scopus 로고    scopus 로고
    • Mechanisms of anti-cancer action and pharmacology of clofarabine
    • Zhenchuk A, Lotfi K, Juliusson G, et al. Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochem Pharmacol 2009;78:1351-9
    • (2009) Biochem Pharmacol , vol.78 , pp. 1351-1359
    • Zhenchuk, A.1    Lotfi, K.2    Juliusson, G.3
  • 24
    • 0032917771 scopus 로고    scopus 로고
    • Antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-β-D- arabinofuranosyl) adenine, a novel deoxyadenosine analog, against human colon tumor xenografts by oral administration
    • DOI 10.1007/s002800050889
    • Takahashi T, Kanaqawa J, Akinaga S, et al. Antitumor activity of 2-chloro-9-(2-deoxy-fluoro-beta-D-arabinofuranosyl) adenine, a novel deoxyadenosine analog m against human colon tumor xenografts by oral administration. Cancer Chemother Pharmacol 1999;43:233-40 (Pubitemid 29042492)
    • (1999) Cancer Chemotherapy and Pharmacology , vol.43 , Issue.3 , pp. 233-240
    • Takahashi, T.1    Kanazawa, J.2    Akinaga, S.3    Tamaoki, T.4    Okabe, M.5
  • 25
  • 26
    • 0020992379 scopus 로고
    • Metabolism of 9-β-D-arabinosyl-2-fluoroadenine-5'-phosphate by mice bearing P388 leukemia
    • Avramis VI, Plunkett W. Metabolism of 9-, 6-D-arabinosyl-2fluoroadenine- 41-phosphate by mice bearing P388 leukemia. Cancer Drug Deliv 1983;1:1-10 (Pubitemid 15188060)
    • (1983) Cancer Drug Delivery , vol.1 , Issue.1 , pp. 1-10
    • Avramis, V.I.1    Plunkett, W.2
  • 27
    • 66749161188 scopus 로고    scopus 로고
    • Oral and intravenous clofarabine for patients with myelodysplastic syndrome
    • abstract 222
    • Faderl S, Garcia-Manero G, Ravandi F, et al. Oral and intravenous clofarabine for patients with myelodysplastic syndrome. Blood 2008;112:abstract 222
    • (2008) Blood , vol.112
    • Faderl, S.1    Garcia-Manero, G.2    Ravandi, F.3
  • 28
    • 77954911871 scopus 로고    scopus 로고
    • Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome
    • Faderl S, Garcia-Manero G, Estrov Z, et al. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol 2010;28:2755-60
    • (2010) J Clin Oncol , vol.28 , pp. 2755-2760
    • Faderl, S.1    Garcia-Manero, G.2    Estrov, Z.3
  • 29
    • 0023854422 scopus 로고
    • Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells
    • Gandhi V, Plunkett W. Modulation of arabinosyl nucleoside metabolism by arabinosyl nucleotides in human leukemia cells. Cancer Res 1988;48:329-34 (Pubitemid 18045766)
    • (1988) Cancer Research , vol.48 , Issue.2 , pp. 329-334
    • Gandhi, V.1    Plunkett, W.2
  • 30
    • 0021847172 scopus 로고
    • Pharmacologically directed ara-C therapy for refractory leukemia
    • Plunkett W, Iacoboni S, Estey E, et al. Pharmacologically directed ara-C therapy for refractory leukemia. Semin Oncol 1985;12:20-30 (Pubitemid 15063578)
    • (1985) Seminars in Oncology , vol.12 , Issue.2 , pp. 20-30
    • Plunkett, W.1    Iacoboni, S.2    Estey, E.3
  • 31
    • 0023470734 scopus 로고
    • Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia
    • Estey E, Plunkett W, Dixon D, et al. Variable predicting response to high-dose cytosine arabinoside therapy in patients with refractory acute leukemia. Leukemia 1987;1:580-3 (Pubitemid 18005688)
    • (1987) Leukemia , vol.1 , Issue.8 , pp. 580-583
    • Estey, E.1    Plunkett, W.2    Dixon, D.3    Keating, M.4    McCredie, K.5    Freireich, E.J.6
  • 32
    • 15044340106 scopus 로고    scopus 로고
    • Biochemical modulation of cytarabine triphosphate by clofarabine
    • DOI 10.1007/s00280-004-0906-y
    • Cooper T, Agus M, Nowak B, et al. Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother Pharmacol 2005;55:361-8 (Pubitemid 40379260)
    • (2005) Cancer Chemotherapy and Pharmacology , vol.55 , Issue.4 , pp. 361-368
    • Cooper, T.1    Ayres, M.2    Nowak, B.3    Gandhi, V.4
  • 33
    • 0023470734 scopus 로고
    • Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia
    • Estey E, Plunkett W, Dixon D, et al. Variable predicting response to high-dose cytosine arabinoside therapy in patients with refractory acute leukemia. Leukemia 1987;1:580-3 (Pubitemid 18005688)
    • (1987) Leukemia , vol.1 , Issue.8 , pp. 580-583
    • Estey, E.1    Plunkett, W.2    Dixon, D.3    Keating, M.4    McCredie, K.5    Freireich, E.J.6
  • 35
    • 18044372314 scopus 로고    scopus 로고
    • Clofarabine plus cytarabine combination is active in newly diagnosed patients ‡ age 50 with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)
    • abstract 875
    • Faderl S, Gandhi V, Verstovsek S, et al. Clofarabine plus cytarabine combination is active in newly diagnosed patients ‡ age 50 with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Blood 2004;104:abstract 875
    • (2004) Blood , vol.104
    • Faderl, S.1    Gandhi, V.2    Verstovsek, S.3
  • 36
    • 80051992418 scopus 로고    scopus 로고
    • Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure
    • Prébet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011;29:3322-7
    • (2011) J Clin Oncol , vol.29 , pp. 3322-3327
    • Prébet, T.1    Gore, S.D.2    Esterni, B.3
  • 37
    • 77956862198 scopus 로고    scopus 로고
    • Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy
    • Jabbour E, Garcia-Manero G, Batty N, et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer 2010;116:3830-4
    • (2010) Cancer , vol.116 , pp. 3830-3834
    • Jabbour, E.1    Garcia-Manero, G.2    Batty, N.3
  • 38
    • 84892386420 scopus 로고    scopus 로고
    • Outcome of patients (pts) with low and intermediate-1 risk myelodysplastic syndrome (MDS) after hypomethylating agent (HMA) failure
    • abstract 388
    • Jabbour E, Garcia-Manero G, Xiao L, et al. Outcome of patients (pts) with low and intermediate-1 risk myelodysplastic syndrome (MDS) after hypomethylating agent (HMA) failure. Blood 2013;122:abstract 388
    • (2013) Blood , vol.122
    • Jabbour, E.1    Garcia-Manero, G.2    Xiao, L.3
  • 39
    • 78650039737 scopus 로고    scopus 로고
    • A phase II study of low dose intravenous clofarabine for elderly patients with myelodysplastic syndrome who have failed 5-azacytidine
    • Lim SH, McMahan J, Zhang J, et al. A phase II study of low dose intravenous clofarabine for elderly patients with myelodysplastic syndrome who have failed 5-azacytidine. Leuk Lymphoma 2010;51(12):2258-61
    • (2010) Leuk Lymphoma , vol.51 , Issue.12 , pp. 2258-2261
    • Lim, S.H.1    McMahan, J.2    Zhang, J.3
  • 40
    • 84892406300 scopus 로고    scopus 로고
    • Clofarabine plus low-dose cytarabine for the treatment of patients with higher-risk myelodysplastic syndrome (MDS) who have been relapsing after, or are refractory to, hypomethylator agent therapy
    • abstract 1525
    • Nazha A, Garcia-Manero G, Kantarjian HM, et al. Clofarabine plus low-dose cytarabine for the treatment of patients with higher-risk myelodysplastic syndrome (MDS) who have been relapsing after, or are refractory to, hypomethylator agent therapy. Blood 2013;122:abstract 1525
    • (2013) Blood , pp. 122
    • Nazha, A.1    Garcia-Manero, G.2    Kantarjian, H.M.3
  • 41
    • 84892423768 scopus 로고    scopus 로고
    • A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and highrisk myelodysplastic syndromes
    • Locke F, Agarwal R, Kunnavakkam R, et al. A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and highrisk myelodysplastic syndromes. Bone Marrow Transplant 2013;17:1-7
    • (2013) Bone Marrow Transplant , vol.17 , pp. 1-7
    • Locke, F.1    Agarwal, R.2    Kunnavakkam, R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.